Nuvectis (NVCT) - Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan

The EV/EBITDA price history for Nuvectis Pharma, Inc. (NVCT), which currently stands at 0.00, demonstrates the valuation of a business generating profit from exclusive rights to anti-cancer agents. Nuvectis Pharma, Inc. (NVCT) is implementing environmental standards in its laboratories and strictly adhering to bioethics. Management is currently focused on accelerating clinical trials for new molecules and seeking major partners among global pharmaceutical behemoths.

NVCT Nuvectis Pharma Inc.: Nilai perusahaan marang bathi operasional sadurunge panyusutan ing interval 23.11.2025 - 14.11.2026

NVCT (nuvectis.com): rincian analitis lan laporan miturut indikator

- rega saham lan target rega konsensus:

Kutipan saham Nuvectis|NVCT - Konsensus nilai wajar

- indikator kapitalisasi pasar:

Nilai pasar Nuvectis Pharma, Inc|NVCT - Total Nilai Perusahaan

- indikator nilai buku ekuitas:

Aset Bersih saben Siji Saham Nuvectis Pharma|NVCT - Kapitalisasi Akuntansi|Rasio Kapitalisasi Pasar marang Nilai Buku nuvectis.com|NVCT - Gunggung Aset Perusahaan

- data utang lan likuiditas:

- data bathi bisnis lan rasio investasi:

NVCT - Penghasilan resik perusahaan|Bathi mangsa ngarep Nuvectis Pharma, Inc.|NVCT - Nilai perusahaan marang bathi resik|Prakiraan rega marang bathi Nuvectis Pharma, Inc.|NVCT - Rasio nilai perusahaan marang wutah bathi|Pangali EV/EBITDA Nuvectis Pharma, Inc|NVCT - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi resik saben saham (EPS TTM) Nuvectis Pharma|NVCT - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan nuvectis.com|NVCT - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Nuvectis Pharma, Inc.

- indikator dodolan lan pendapatan:

NVCT - Pendapatan lan volume dodolan|Prakiraan pendapatan perusahaan Nuvectis|NVCT - Rasio rega marang dodolan|Multiplikator forward rega marang pendapatan Nuvectis Pharma, Inc

Ringkesan analitik perusahaan:NVCT (Nuvectis)

Nuvectis Pharma, Inc. (NVCT) monetizes a unique HSF1 suppression mechanism, ensuring significant pricing power within the resistant oncology segment. The calculated metric combines market capitalization and net debt, benchmarking them against EBITDA. This metric allows for an assessment of the business's real value, stripped of debt burdens and fiscal distortions. Analyzing the EV/EBITDA multiple, accounting for net debt, helps identify phases of asset overheating or undervaluation.

Analisis pesaing